Related Experiment Video
Updated: Jun 14, 2025
Retinal Pathophysiological Evaluation in a Rat Model
Published on: May 6, 2022
Cannabinoid Receptor 2 Agonism Demonstrates Therapeutic Potential in Experimental Models of Relevance to Diabetic
Cayla D Ontko1, Taylor E Smith2, Amy K Stark3
1Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN.
Article Highlights:
An effective treatment strategy for early-stage diabetic retinopathy (DR) could delay or prevent disease progression and limit or eliminate irreparable retinal damage and vision loss associated with progression to later stages of DR. Cannabinoid receptor 2 (CB2) activation strategies may provide a promising therapeutic approach to address the chronic retinal inflammation that encourages DR progression. CB2 activation therapeutically addresses leukocyte binding in human retinal microvascular endothelial cells and retinal leukostasis in diabetic mice, presumably by inhibiting nuclear factor κB-dependent transcription of adhesion molecules VCAM-1 and ICAM-1. CB2 agonism constitutes a rational therapeutic approach for clinical application to patients with early-stage DR.
Insights
Cannabinoid receptor 2 (CB2) agonists HU-308 and CB65 effectively reduced inflammation and leukocyte adhesion in models of diabetic retinopathy (DR). This suggests CB2 agonism is a promising therapeutic strategy for early-stage DR, potentially preventing vision loss.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Diabetic retinopathy (DR) is characterized by retinal vascular inflammation.
- Inflammatory cytokines TNFα and IL-1β contribute to DR progression and leukostasis.
- Cannabinoid receptor 2 (CB2) agonism shows potential for treating nonocular inflammatory conditions.
Purpose of the Study:
- To evaluate the efficacy of CB2 agonists (HU-308, CB65) in mitigating leukocyte adhesion and inflammation in diabetic retinopathy models.
- To investigate the therapeutic potential of CB2 agonism for early-stage DR treatment.
Main Methods:
- In vitro studies using human retinal microvascular endothelial cells (hRMEC) exposed to inflammatory stimuli.
- In vivo studies using murine models of DR.
- Assessed gene and protein expression of adhesion molecules (ICAM1, VCAM1, SELE).
- Measured leukocyte adhesion and nuclear factor κB (NF-κB) translocation.
Main Results:
- HU-308 and CB65 significantly reduced inflammatory gene and protein expression of adhesion molecules in hRMEC.
- CB2 agonists inhibited leukocyte adhesion to hRMEC monolayers.
- HU-308 and CB65 decreased NF-κB translocation and activation.
- In vivo, HU-308 administration reduced retinal leukostasis in DR models.
Conclusions:
- CB2 agonism effectively attenuates key inflammatory processes in diabetic retinopathy.
- CB2 agonists demonstrate therapeutic potential for managing retinal leukostasis in DR.
- Targeting CB2 receptors offers a rational approach for clinical application in early-stage DR.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:25Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
01:15G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...